Core Insights - Hims & Hers Health's stock dropped 25% after the company announced it would cease selling its compounded semaglutide weight-loss pill, just days after its launch, due to legal action from Novo Nordisk [1][1][1] - Novo Nordisk has filed a lawsuit against Hims & Hers, seeking to permanently ban the sale of unapproved compounded drugs that infringe on its patents and is pursuing damages [1][1][1] - Hims & Hers has faced significant stock depreciation, losing over 60% of its value in the past 12 months, while Novo Nordisk's shares have decreased by approximately 40% during the same period [1][1][1] Company Developments - Hims & Hers announced the discontinuation of its compounded weight-loss pill, which was marketed as having the same active ingredient as Novo Nordisk's Wegovy, following legal threats from Novo Nordisk [1][1][1] - The lawsuit from Novo Nordisk is described by Hims & Hers as a "blatant attack" on Americans who rely on compounded medications, indicating the company's intent to continue advocating for access to these treatments [1][1][1] Industry Context - The FDA has indicated plans to restrict the use of GLP-1 active ingredients in compounded weight-loss medications, specifically mentioning Hims & Hers in its statement [1][1][1] - Eli Lilly is anticipated to receive FDA approval for its own weight-loss pill later this year, which could further impact competition in the weight-loss drug market [1][1][1]

A box of Wegovy pills arranged at a pharmacy in Provo, Utah, US, on Thursday, Jan. 15, 2026.The Food and Drug Administration said Novo Nordisk's TV advertisement for its newly launched Wegovy pill for obesity included "false or misleading" claims about the medicine's abilities and benefits to patients.In a letter to Novo dated Feb. 5, the FDA said the ad misbrands the oral drug, making its distribution a violation of federal law. The agency requested that the drugmaker take immediate action to address the v ...

Core Insights - Hims & Hers Health's stock plummeted 25% following the announcement of its plan to sell a compounded version of Wegovy for $49 per month, significantly undercutting Novo Nordisk's pricing [1][4] - Novo Nordisk responded with a lawsuit against Hims & Hers, seeking a permanent ban on the sale of its Ozempic lookalike pill and any compounded versions of its drugs [5][6] - The FDA indicated it would take action against Hims & Hers, potentially restricting access to necessary ingredients for manufacturing similar products [2][4] Company Actions - Hims & Hers initially planned to sell a pill version of Ozempic but reversed its decision by Saturday, indicating a retreat in the face of legal and regulatory pressure [3][4] - The company gambled on the FDA's leniency regarding the copying of Novo Nordisk's GLP-1 weight loss drug but ultimately faced significant legal challenges [4][5] Legal Implications - Novo's lawsuit targets Hims & Hers' ability to compound GLP-1 weight loss drugs using semaglutide, which could result in the loss of Hims & Hers' GLP-1 business if Novo wins [6] - The lawsuit emphasizes Novo's enforcement of its patent rights, which could have broader implications for the telehealth company's product offerings [6]

Core Viewpoint - Hims & Hers has abandoned its plan to offer a compounded version of the weight-loss drug Wegovy, following threats from the FDA and legal action from Novo Nordisk, the original manufacturer of Wegovy [1][1][1] Company Actions - Hims & Hers announced the decision to drop the compounded semaglutide pill just two days after its introduction, citing constructive conversations with industry stakeholders [1][1] - The company had initially planned to sell its version of Wegovy at a significantly lower price of $49 for the first month and $99 thereafter, compared to Novo's price of $149 per month [1][1][1] Regulatory Environment - The FDA indicated plans to restrict access to the active ingredients necessary for compounding popular GLP-1 drugs, which include Wegovy, Ozempic, and Zepbound [1][1] - The FDA has stated that GLP-1 drugs are no longer in shortage as of 2024, which is expected to end the practice of compounding these medications [1][1] Market Context - Hims & Hers, along with other companies, entered the multibillion-dollar market for obesity medications, driven by the high demand for GLP-1 drugs [1][1] - The compounded version of the semaglutide pill that Hims planned to sell was not FDA-approved and had not undergone trials to prove its effectiveness [1][1]

Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired.By [George Glover]ShareResize---ReprintsIn this a ...

来源：滚动播报 诺和诺德股价回吐部分涨幅，最新涨 5.2%。 ...

Group 1 - The FDA has deemed a television advertisement for Novo Nordisk's weight loss pill as "false or misleading" [1] - The communication from the FDA was documented in a letter dated February 5 [1]

Core Insights - Novo Nordisk's shares faced significant pressure due to a disappointing 2026 outlook, overshadowing a strong fourth-quarter performance [1] - Hims & Hers Health's announcement to launch a compounded oral semaglutide pill intensified competition in the weight-loss market, posing a threat to Novo Nordisk's flagship product, Wegovy [2][3] - The FDA's intervention against non-FDA-approved compounded GLP-1 drugs provided a temporary relief for Novo Nordisk's stock, which rebounded sharply [6] Company Performance - Novo Nordisk's stock has declined by 4.5% over the past six months, underperforming the industry growth of 34.5% [11] - The company's shares are trading at a price/earnings ratio of 14.31, lower than the industry average of 18.76 and significantly below its five-year mean of 29.25 [14] Market Dynamics - The obesity treatment market is becoming increasingly competitive, with Eli Lilly also advancing its GLP-1-based drugs and seeking approval for an oral GLP-1 pill [8] - The introduction of lower-priced alternatives, such as Hims' $49 compounded pill, raises concerns about pricing power and demand for Novo Nordisk's products [4][9] Regulatory Environment - The FDA has issued warnings against misleading marketing of compounded GLP-1 drugs, which could impact companies like Hims & Hers Health [6] - Novo Nordisk has indicated potential legal actions to protect its intellectual property and patient safety in response to the competitive threat [5] Earnings Estimates - Earnings estimates for Novo Nordisk have declined, with 2026 estimates dropping from $3.55 to $3.32 per share and 2027 estimates from $3.65 to $3.39 [17]

Group 1 - The U.S. stock market showed mixed results, with major indices fluctuating and most Chinese concept stocks declining [1] - Nvidia experienced a significant intraday surge, rising over 4%, with Goldman Sachs analysts projecting Q4 2025 revenue to reach $67.3 billion, exceeding market expectations [3] - Oracle's stock surged nearly 9.6%, marking its largest intraday gain since December of the previous year, following an upgrade from Davidson Investment Bank from "neutral" to "buy" [3] Group 2 - Storage stocks weakened, with Micron Technology falling nearly 2.5% and SanDisk dropping over 1.4%, as Nvidia may exclude Micron's HBM4 from the first-year production of its Rubin architecture [5] - The weight loss drug sector saw gains, with Novo Nordisk rising over 5% and Eli Lilly increasing nearly 1%, while Hims & Hers plummeted over 25% due to a lawsuit related to a generic version of semaglutide [5] - The gold and silver markets rebounded significantly, with spot gold rising over 1.4% to nearly $5,040 per ounce and spot silver increasing over 5% to $81.696 per ounce [5][6] Group 3 - International oil prices saw a short-term rise, with WTI crude oil and ICE Brent crude both increasing by 1%, and WTI crude surpassing $64 per barrel [6] - Upcoming U.S. non-farm payroll and CPI reports are expected to provide crucial insights into the Federal Reserve's monetary policy direction, with potential for significant market volatility if the data indicates "weak employment + stubborn inflation" [7] Group 4 - The UK faced a "triple whammy" in its stock, bond, and currency markets, with the FTSE 100 index and GBP/EUR exchange rate both plummeting, and the 10-year government bond yield approaching its highest point since November of the previous year [9] - The resignation of two senior officials from the UK Prime Minister's office within 24 hours has raised concerns about political stability, which may impact market confidence [9]

| Hims & Hers Health Inc-A (Ai) [ Q | | | --- | --- | | HIMS | | | 16.350 16.923 >> | 17.825 最高 17.900 最低 | | 3.25亿 -26.49% -6.097 快手 | 8.05% 总量 1833万股 金额 | | 盘前 09:30 美东 V | 17.830 -5.190 -22.55% | | 国 年报预披露: 于2026-02-23(美东)盘后披露2025财年年报 ( ... ● | | | 均价:17.712 最新:16.923 -6.097 -26.49% | | | 29.561 | | | 300 9:36 16.950 | | | 9:36 16.950 141 | | | 23.020 - 9:36 16.9601 100 | | | 9:36 16.960 100 | | | 9:36 16.960 125 | | | 100 9:36 16.9234 | | | 9:36 16.940↑ 100 | | | 9:36 16.960↑ 500 | | | -28.42% 9:36 16.9 ...